HOXB-AS3 and acute myeloid leukemia: Finally, short-term in vivo treatment of human AML blasts in murine xenografts revealed that HOXB-AS3 KD led to a decrease in the amount of the transcribed rRNA species (P < 0.001; Fig. 5f) and a decrease in the de novo protein synthesis in these cells (P = 0.01; Figs. 5g and h).